Sol-Gel Technologies Ltd. (SLGL) Analysts See $-0.44 EPS

August 12, 2018 - By Joseph Norton

Analysts expect Sol-Gel Technologies Ltd. (NASDAQ:SLGL) to report $-0.44 EPS on August, 21.After having $-0.39 EPS previously, Sol-Gel Technologies Ltd.’s analysts see 12.82 % EPS growth. The stock increased 2.03% or $0.13 during the last trading session, reaching $6.54. About 2,278 shares traded. Sol-Gel Technologies Ltd. (NASDAQ:SLGL) has 0.00% since August 13, 2017 and is . It has underperformed by 12.57% the S&P500.

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company has market cap of $123.93 million. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It currently has negative earnings. It is also involved in the development of generic dermatological drug products.

More recent Sol-Gel Technologies Ltd. (NASDAQ:SLGL) news were published by: Globenewswire.com which released: “Sol-Gel Technologies Reports Second Quarter 2018 Financial Results” on August 08, 2018. Also Benzinga.com published the news titled: “The Week Ahead: Apple And Tesla Earnings, FOMC Meeting, Sonos IPO” on July 31, 2018. Streetinsider.com‘s news article titled: “UPDATE: HC Wainwright Starts Sol Gel Technologies Ltd. (SLGL) at Buy” with publication date: July 16, 2018 was also an interesting one.

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.